BACKGROUND: A guideline for the treatment of fibromyalgia syndrome (FMS) was developed in cooperation with 10 German medical and psychological associations and 2 patient self-help groups. METHODS: A systematic literature search including all controlled studies evaluating multicomponent therapy (MT) was performed in the Cochrane Library (1993-12/2006), Medline (1980-12/2006), PsychInfo (1966-12/2006) and Scopus (1980-12/2006). Levels of evidence were assigned according to the classification system of the Oxford Centre for Evidence-Based Medicine. Grading of the strengths of recommendations was done according to the German program for disease management guidelines. Standardized procedures to reach a consensus on recommendations were used. RESULTS: MT is superior to control groups or routine treatment (evidence level 1A) and should be offered to FMS patients (recommendation strength A). CONCLUSIONS: Future studies should consider medication, other co-therapies and comorbidities. MT programs tailored to FMS subgroups should be tested.
BACKGROUND: A guideline for the treatment of fibromyalgia syndrome (FMS) was developed in cooperation with 10 German medical and psychological associations and 2 patient self-help groups. METHODS: A systematic literature search including all controlled studies evaluating multicomponent therapy (MT) was performed in the Cochrane Library (1993-12/2006), Medline (1980-12/2006), PsychInfo (1966-12/2006) and Scopus (1980-12/2006). Levels of evidence were assigned according to the classification system of the Oxford Centre for Evidence-Based Medicine. Grading of the strengths of recommendations was done according to the German program for disease management guidelines. Standardized procedures to reach a consensus on recommendations were used. RESULTS: MT is superior to control groups or routine treatment (evidence level 1A) and should be offered to FMS patients (recommendation strength A). CONCLUSIONS: Future studies should consider medication, other co-therapies and comorbidities. MT programs tailored to FMS subgroups should be tested.
Authors: Daniel H Solomon; Asra Warsi; Tina Brown-Stevenson; Maureen Farrell; Suzanne Gauthier; Debra Mikels; Thomas H Lee Journal: J Rheumatol Date: 2002-02 Impact factor: 4.666
Authors: C Cedraschi; J Desmeules; E Rapiti; E Baumgartner; P Cohen; A Finckh; A F Allaz; T L Vischer Journal: Ann Rheum Dis Date: 2004-03 Impact factor: 19.103
Authors: B Arnold; W Häuser; M Arnold; M Bernateck; K Bernardy; W Brückle; E Friedel; H J Hesselschwerdt; W Jäckel; V Köllner; E Kühn; F Petzke; M Settan; M Weigl; E Winter; M Offenbächer Journal: Schmerz Date: 2012-06 Impact factor: 1.107
Authors: Winfried Häuser; Wolfgang Eich; Markus Herrmann; Detlev O Nutzinger; Marcus Schiltenwolf; Peter Henningsen Journal: Dtsch Arztebl Int Date: 2009-06-05 Impact factor: 5.594
Authors: B Arnold; H-R Casser; K Klimczyk; J Lutz; T Brinkschmidt; I Gralow; D Irnich; U Kaiser; B Nagel; M Schiltenwolf; M Pfingsten; R Sabatowski; W Söllner Journal: Schmerz Date: 2015-12 Impact factor: 1.107
Authors: Jason W Busse; Shanil Ebrahim; Gaelan Connell; Eric A Coomes; Paul Bruno; Keshena Malik; David Torrance; Trung Ngo; Karin Kirmayr; Daniel Avrahami; John J Riva; Peter Struijs; David Brunarski; Stephen J Burnie; Frances LeBlanc; Ivan A Steenstra; Quenby Mahood; Kristian Thorlund; Victor M Montori; Vishalini Sivarajah; Paul Alexander; Milosz Jankowski; Wiktoria Lesniak; Markus Faulhaber; Małgorzata M Bała; Stefan Schandelmaier; Gordon H Guyatt Journal: Syst Rev Date: 2013-03-13
Authors: Winfried Häuser; Bernhard Arnold; Wolfgang Eich; Eva Felde; Christl Flügge; Peter Henningsen; Markus Herrmann; Volker Köllner; Edeltraud Kühn; Detlev Nutzinger; Martin Offenbächer; Marcus Schiltenwolf; Claudia Sommer; Kati Thieme; Ina Kopp Journal: Ger Med Sci Date: 2008-12-09